Stereotaxis(US:STXS)2026-03-09 21:32Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in Q4 2024 [29] - Full year revenue for 2025 was $32.4 million, up from $26.9 million in 2024 [29] - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [30] - Operating loss for Q4 2025 was $5.6 million, compared to $7.6 million in Q4 2024 [31] - Adjusted operating loss for the full year 2025 was $9.3 million, improved from $12.4 million in 2024 [32] Business Line Data and Key Metrics Changes - System revenue for Q4 2025 was $3.3 million, reflecting partial revenue recognition on two Genesis systems [29] - Recurring revenue for Q4 2025 was $5.3 million, down from $9.4 million in Q4 2024, impacted by initial sales of new catheters [29] - Full year system revenue was $10.2 million, compared to $8.6 million in the prior year [29] - Full year recurring revenue was $22.2 million, up from $18.3 million in 2024, driven by increased catheter revenue [30] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion annually to $20 billion by 2030 [11] - The company views the market opportunity for robotics in EP as a $2 billion opportunity [12] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available without requiring significant construction [9] - The strategy includes building an ecosystem of catheters, leveraging core technology for broader endovascular surgery applications, and establishing a digital backbone for connectivity [10] - Regulatory approvals for the GenesisX robot and associated catheters were achieved, marking a significant milestone [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming manufacturing challenges and anticipates significant commercial and strategic value creation in 2026 [19] - The company expects to deliver double-digit revenue growth in 2026, with quarterly revenue projected to ramp above $10 million in the latter half of the year [34] - Management highlighted the importance of establishing GenesisX programs and ramping catheter manufacturing to support revenue growth [19][21] Other Important Information - The company generated $4 million from a registered direct financing and $3.1 million from an at-the-market offering [33] - Cash and cash equivalents as of December 31, 2025, were $13.4 million with no debt [33] Q&A Session Summary Question: What is the goal for GenesisX programs and the mix of sales? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [38] Question: What is included in the $3 million revenue goal for Synchrony in 2026? - The revenue guidance focuses on capital sales of Synchrony systems, with expectations for several hospitals to standardize their EP labs on Synchrony [41] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working closely with physicians to manage expectations and supply [46] Question: What are the economic models for GenesisX placements? - There are three core models: outright capital sale, lease, and placement with disposable commitments, with a mix expected in deals [71] Question: What is the outlook for operating expenses in 2026? - Management expects operating expenses to remain stable year-over-year, with adjustments based on project milestones and investments in manufacturing and commercial activities [80]